Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. reported Form 4 activity for entities associated with Fairmount Funds Management LLC. Fairmount Healthcare Fund II L.P. converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, based on a 40-to-1 conversion ratio subject to a 9.99% beneficial ownership limitation.
On the same date, Fairmount Healthcare Fund II L.P. sold 4,684,781 shares of Common Stock at $85.31 per share, leaving it with no directly held Common Stock after the transaction, while retaining indirect exposure through Series A Preferred Stock that is convertible into 13,841,800 shares of Common Stock. Fairmount, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Spyre Therapeutics’ major shareholder Fairmount Funds and related individuals updated their ownership disclosures in this Schedule 13D amendment. Fairmount’s Fund II converted 16,667 shares of Series B Preferred Stock into 666,680 common shares for no cash consideration under the preferred stock terms.
On June 23, 2026, Fund II sold 4,684,781 common shares in a block trade at $85.31 per share. After these changes and applying a 9.99% beneficial ownership cap, the reporting group’s position includes 8,581,440 shares issuable from Series A Preferred Stock plus 228,646 option shares, representing up to about 10% of Spyre’s common stock.
The filing also notes that director Peter Harwin resigned from Spyre’s board on May 27, 2026, and states his resignation was not due to any disagreement with the company on its operations, policies, or practices.
Spyre Therapeutics director Michael Thomas Henderson reported an open-market sale of Common Stock. He sold 20,000 shares on June 22, 2026 at a price of $100.00 per share. After this transaction, he directly holds 68,606 shares of Spyre Therapeutics common stock.
According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating the trades were scheduled in advance rather than timed discretionarily.
SYRE submitted a Form 144 notice relating to proposed resale transactions. The filing lists 20,000 Restricted Stock Units dated 08/28/2024 as securities to be sold and reports prior 10b5-1 sales by Michael Henderson of 80,000 shares on 05/08/2026 for $5,952,034. The filing names Morgan Stanley Smith Barney LLC as the broker and references 06/22/2026 in the header.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY002 in moderately-to-severely active ulcerative colitis. SPY002 met its primary endpoint with a statistically significant 10.7-point reduction in Robarts Histopathology Index score at Week 12 (p<0.0001).
Key secondary measures included clinical remission by modified Mayo Score in 33% of patients and endoscopic improvement in 42%. SPY002 was described as well tolerated: 41.7% of the 48 treated patients experienced treatment-emergent adverse events, with two serious events deemed not drug-related, three drug-related adverse events, no adverse events of special interest, and no deaths.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported an option exercise and related share sale. Sloan exercised stock options to acquire 8,333 shares of common stock at $27.46 per share, then sold 8,333 shares in an open‑market transaction at $75.00 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Sloan continues to hold 8,333 common shares directly and 313,334 stock options exercisable for common stock, with the option award originally covering 400,000 shares and expiring on October 1, 2034.
Spyre Therapeutics, Inc. reported that Chief Executive Officer and director Cameron Turtle sold a total of 15,000 shares of common stock in three open-market transactions on June 1, 2026 at prices ranging from the high-$60s to low-$70s per share. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025, indicating they were pre-arranged. Following the transactions, the filing shows Turtle directly holding 597,540 shares of common stock, which includes 87,138 shares that vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics (SYRE) Chief Financial Officer Scott L. Burrows exercised stock options and sold shares in a pre-planned transaction. On June 1, 2026, he exercised options to acquire 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in three open-market trades at weighted-average prices around the low $70s, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly holds 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments in 2026 and 2027, and continues to hold a large stock option covering hundreds of thousands of additional shares.
SYRE filed a Rule 144 notice reporting a planned sale of 16,667 shares via exercise of stock options on 06/03/2026. The filing also lists prior 10b5-1 sales: 78,333 shares on 05/01/2026 for $5,600,884.57 and 7,958 shares on 04/01/2026 for $397,900.00.
Spyre Therapeutics reported an amendment to its SPY003 license agreement with Paragon Therapeutics. The change expands Spyre’s rights from only inflammatory bowel disease to all therapeutic, prophylactic, palliative and diagnostic uses for SPY003.
This broader license is subject to dosing limits. Spyre will not dose human patients with SPY003 outside inflammatory bowel disease in a clinical trial as part of a combination before June 1, 2028, or as a monotherapy before June 1, 2030, under what is termed the Monotherapy Dosing Restriction.
If Spyre or a Paragon licensee completes a material transaction, such as a change of control, any remaining restrictions outside the original inflammatory bowel disease field will end on June 1, 2028. The full terms are set out in the filed amendment.